公开(公告)号：EP2900246B1

公开(公告)日：2020-03-25

申请号：EP12885828.9

申请日：2012-09-27

申请人： SolAeroMed Inc.

发明人： AMREIN, Mathias W. ,  GUNASEKARA, Lasantha C. ,  PRATT, Ryan

IPC分类号： A61K31/724 ,  A61P39/04

公开(公告)号：EP1962869B1

公开(公告)日：2013-03-20

申请号：EP06840529.9

申请日：2006-12-21

申请人： SolAeroMed Inc.

发明人： GREEN, Francis, H. Y. ,  EL MAYS, Tamer, Y. ,  SCHURCH, Samuel

IPC分类号： A61K31/02 ,  A61K33/00 ,  A61P11/00 ,  A61P11/06

CPC分类号： A61K33/00 ,  A61K9/007 ,  A61K9/0073 ,  A61K9/0078 ,  A61K31/02 ,  A61K31/025 ,  A61K31/131 ,  A61K31/137 ,  A61K31/352 ,  A61K2300/00

公开(公告)号：EP3204097A1

公开(公告)日：2017-08-16

申请号：EP15848881.7

申请日：2015-10-08

申请人： Solaeromed Inc.

发明人： DENNIS, John H. ,  MCAFFER, Ian G. C. ,  DALBERG, Stefan ,  GREEN, Francis ,  CLARK, Andy

IPC分类号： A61M11/02 ,  A61K31/02 ,  A61K31/025 ,  A61K31/131 ,  A61K31/341 ,  A61K9/72 ,  A61M15/00 ,  A61P11/00 ,  A61P21/02

CPC分类号： A61M11/02 ,  A61K31/02 ,  A61M11/003 ,  A61M11/04 ,  A61M15/0025 ,  A61M15/009 ,  A61M2202/0476 ,  A61M2205/7536 ,  A61M2205/8225 ,  A61M2210/1035

摘要： Disclosed are apparatus and methods for producing and delivering vapour medicament. An exemplary apparatus disclosed comprises: a gas inlet for receiving a gas from a source of pressurized gas; a chamber for receiving a liquid medicament therein, the chamber being in communication with the gas inlet for permitting entrance and expansion of the gas in the chamber in the presence of the liquid medicament to produce the vapour medicament; and a vapour outlet in communication with the chamber for delivering the vapour medicament.

摘要翻译： 公开了用于生产和输送蒸汽药剂的设备和方法。 所公开的示例性设备包括：用于接收来自加压气体源的气体的气体入口; 用于在其中接收液体药剂的腔室，腔室与气体入口连通以允许在存在液体药剂的情况下腔室中的气体进入和扩展以产生蒸气药剂; 以及与腔室连通以输送蒸气药剂的蒸气出口。

公开(公告)号：EP2900246A1

公开(公告)日：2015-08-05

申请号：EP12885828.9

申请日：2012-09-27

申请人： SolAeroMed Inc.

发明人： AMREIN, Mathias W. ,  GUNASEKARA, Lasantha C. ,  PRATT, Ryan

IPC分类号： A61K31/724 ,  A61P39/04

CPC分类号： A61K33/40 ,  A61K31/724

摘要： The use of cholesterol-sequestering agents, such as methyl-beta-cyclodextrin, for the treatment of pulmonary surfactant dysfunction is disclosed. It was discovered that oxidative damage to pulmonary surfactant arises due to the interaction between reactive oxygen species and cholesterol. Thus, by removing cholesterol from pulmonary7 surfactant through the addition of a cholesterol-sequestering agent, oxidative damage to the surfactant is mitigated. It was also shown that methyl-beta-cyclodextrin can restore normal function to dysfunctional surfactant removed from the lungs of children with cystic fibrosis and non cystic fibrosis bronchiolitis.

公开(公告)号：EP3204097A4

公开(公告)日：2018-06-13

申请号：EP15848881

申请日：2015-10-08

申请人： SOLAEROMED INC

发明人： DENNIS JOHN H ,  MCAFFER IAN G C ,  DALBERG STEFAN ,  GREEN FRANCIS ,  CLARK ANDY

IPC分类号： A61M11/02 ,  A61K9/72 ,  A61K31/02 ,  A61K31/025 ,  A61K31/131 ,  A61K31/341 ,  A61M11/00 ,  A61M11/04 ,  A61M15/00 ,  A61P11/00 ,  A61P21/02

CPC分类号： A61M11/02 ,  A61K31/02 ,  A61M11/003 ,  A61M11/04 ,  A61M15/0025 ,  A61M15/009 ,  A61M2202/0476 ,  A61M2205/7536 ,  A61M2205/8225 ,  A61M2210/1035

摘要： Disclosed are apparatus and methods for producing and delivering vapour medicament. An exemplary apparatus disclosed comprises: a gas inlet for receiving a gas from a source of pressurized gas; a chamber for receiving a liquid medicament therein, the chamber being in communication with the gas inlet for permitting entrance and expansion of the gas in the chamber in the presence of the liquid medicament to produce the vapour medicament; and a vapour outlet in communication with the chamber for delivering the vapour medicament.

公开(公告)号：EP2900246A4

公开(公告)日：2016-04-13

申请号：EP12885828

申请日：2012-09-27

申请人： SOLAEROMED INC

发明人： AMREIN MATHIAS W ,  GUNASEKARA LASANTHA C ,  PRATT RYAN

IPC分类号： A61K31/724 ,  A61P39/04

CPC分类号： A61K33/40 ,  A61K31/724

摘要： The use of cholesterol-sequestering agents, such as methyl-beta-cyclodextrin, for the treatment of pulmonary surfactant dysfunction is disclosed. It was discovered that oxidative damage to pulmonary surfactant arises due to the interaction between reactive oxygen species and cholesterol. Thus, by removing cholesterol from pulmonary7 surfactant through the addition of a cholesterol-sequestering agent, oxidative damage to the surfactant is mitigated. It was also shown that methyl-beta-cyclodextrin can restore normal function to dysfunctional surfactant removed from the lungs of children with cystic fibrosis and non cystic fibrosis bronchiolitis.